KRAS and pancreatic ductal adenocarcinoma: In pancreatic ductal adenocarcinoma, the KRAS oncogene is responsible for >90% of the cases.[24] A population of pancreatic cells survives after ablation of the KRAS oncogene, and they retain tumorigenic potential.